Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07738822) titled 'A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA' on July 28.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Cullinan Therapeutics Inc.
Condition:
Immune Thrombocytopenia (ITP)
Warm Autoimmune Hemolytic Anemia (WAIHA)
Intervention:
Drug: Velinotamig specified dose on specified days.
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: December 2026
Target Sample Size: 72
Countries of Recruitment:
United...